Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585488 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
A Phase 1 study of Metastatic Solid Tumors and Advanced Colorectal Cancer, sponsored by BeiGene.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 514
- Enrollment target
- 17
- Study locations
NCT06585488 is a Phase 1 study of Metastatic Solid Tumors and Advanced Colorectal Cancer that is actively recruiting participants, run by BeiGene. The registered enrollment target is 514 participants, above the 181-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (184% higher). The trial reports 17 study locations across 12 states.
The verdict
NCT06585488, a Phase 1 study of Metastatic Solid Tumors and Advanced Colorectal Cancer, is actively recruiting participants, sponsored by BeiGene.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 514 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy in participants with advanced or metastatic solid tumors harboring KRAS mutations or amplification, as well as when used in combination with tislelizumab (also known as BGB-A317) in participants with nonsquamous non-small cell lung cancer (NSCLC) and used in combination with cetuximab in participants with colorectal cancer (CRC). The study consists of 2 phases: Phase 1a Dose Escalation and Safety Expansion and Phase 1b Dose Expansion.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG Cetuximab
- DRUG BGB-53038
Study Locations (17)
Seoul Teugbyeolsi
- Samsung Medical Center - GangnamGu
- Severance Hospital Yonsei University Health System - SeodaemunGu
- Seoul National University Hospital - Seoul
- Asan Medical Center - SongpaGu
Victoria
- Monash Health - Clayton
- Peter Maccallum Cancer Centre - Melbourne
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
- Beijing Cancer Hospital - Beijing
California
- Usc Norris Comprehensive Cancer Center (Nccc) - Los Angeles
Kansas
- University of Kansas Medical Center Research Institute - Kansas City
Maryland
- Sidney Kimmel Comprehensive Cancer At Johns Hopkins - Baltimore
Texas
- The University of Texas Md Anderson Cancer Center - Houston
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06585488
The ClinicalTrials.gov registry entry for NCT06585488 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 181-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (184% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Tislelizumab is the first listed.
NCT06585488 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Seoul Teugbyeolsi, Victoria, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT06585488 about?
NCT06585488 is a clinical study titled "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification". This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy in participants with advanced or metastatic solid tumors har...
What is the current status of trial NCT06585488?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 514 participants. The study started on 2024-11-26. Estimated completion is 2026-12.
What conditions does trial NCT06585488 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Advanced Non-squamous Non-small-cell Lung Cancer.
What interventions are being tested in trial NCT06585488?
The interventions under investigation include: Tislelizumab (DRUG), Cetuximab (DRUG), BGB-53038 (DRUG).
Who is sponsoring clinical trial NCT06585488?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585488 being conducted?
This trial has 17 study locations across California, Kansas, Maryland, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SLV-324 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.